Alberto
Carmona Bayonas
Asociado Ciencias de la Salud
Complexo Hospitalario Universitario da Coruña
La Coruña, EspañaPublicacions en col·laboració amb investigadors/es de Complexo Hospitalario Universitario da Coruña (4)
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15